Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by BridgeBio Pharma, Inc.
< Previous
1
2
Next >
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
January 10, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
January 03, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)
January 03, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia
December 13, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
December 08, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
December 05, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
November 12, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessions 2023
November 09, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
November 08, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update
November 02, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 11, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)
October 10, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
October 09, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments
October 03, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Announces $250 Million Private Placement Equity Financing
September 25, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 08, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
September 07, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia
September 06, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023
August 27, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023
August 24, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 04, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update
August 03, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-girdle Muscular Dystrophy Type 2I (LGMD2I/R9) Based on Glycosylated Alpha-dystroglycan (⍺DG) Levels and Announces First Patient Dosed in FORTIFY Phase 3 Study
July 31, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 18, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio announces consistently positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
July 17, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio to Host Investor Call to Share Topline 30-month Results from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy on July 17, 2023
July 14, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
Burjeel Holdings to Launch Rare Disease Research & Development Project ‘NADER’ in Partnership with US-based BridgeBio Pharma
July 12, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Presents Updated Six Month Results from its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia at the Endocrine Society (ENDO) 2023 Annual Conference
June 20, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 13, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual Conference
June 08, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.